Slide 1: Q3 FY25 Earnings
Q3 FY25 EARNINGS JUNE 27, 2025
Slide 2: Forward-Looking Statements and Non-GAAP Measures
Forward-Looking Statements and Non-GAAP Measures Statements made in this presentation that are not historical are forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. In addition to statements with respect to guidance, the terms “outlook
Slide 3: Q3 Fiscal 2025 Revenue
Q3 Fiscal 2025 Revenue ($ in millions) Net Sales Net Sales Organic 3Q25 3Q24 Change Growth* Industrial Tools & Service (IT&S) $153 $146 5.1% 1.5% IT&S Product $124 $118 5.6% 1.0% IT&S Service $29 $28 3.1% 3.4% Other (Cortland Biomedical) $5 $4 18.7% 18.7% Enerpac Tool Group $159 $150 5.5% 2.0% *Orga
Slide 4: IT&S Organic Growth by Region
IT&S Organic Growth by Region * Region 3Q25 3Q24 FY24 IT&S Regional Sales APAC 13% Americas 46% EMEA 41% *Organic revenue growth excludes the impact of foreign exchange rates, acquisitions, and dispositions. 4 LSD = low single digit, MSD = mid single digit, HSD = high single digit, LDD = low double
Slide 5: Q3 Fiscal 2025 Profitability
Q3 Fiscal 2025 Profitability ($ in millions, except EPS) YoY 3Q25 3Q24 Change Gross Margin 50.4% 51.8% -140 bps Adjusted SG&A * 25.5% 27.0% -160 bps Adjusted EBITDA* $41 $40 3% Adjusted EBITDA Margin 25.9% 26.4% -50 bps Adjusted EPS* $0.51 $0.47 9% *Adjusted SG&A, adjusted EBITDA, and adjusted EPS a
Slide 6: FY25 Guidance
NET SALES FY25 Guidance Expecting to deliver towards the lower $610 - $625M ~0-2% Organic Growth ~3-6% Total Growth half of the range on Sales, Adjusted EBITDA, and Free Cash Flow ADJ. EBITDA* Key Assumptions: ▪ Targeting to outperform industry and gain market share ▪ No broad-based global recession
Slide 7: Strong Liquidity & Balanced Capital
Strong Liquidity & Balanced Capital Balance Sheet Allocation Strategy ($ in millions) Cash & Equivalents $141 Revolver Capacity (Undrawn) $399 Total Liquidity $539 Total Debt $191 Invest in Ourselves Disciplined M&A Net Debt/Adj. EBITDA* 0.4x Investments in Digital, Product Innovation, R&D, Operatio
Slide 8: Well Positioned to Mitigate Tariffs
Well Positioned to Mitigate Tariffs Goal to remain at least price/cost neutral Mitigation Actions: • Global manufacturer with ability to flex capacity and shift certain aspects of production as needed. • Time tested successful playbook, with flexible supply chain and in-house capabilities for UNITED
Slide 9: New Global Innovation Lab Improves R&D Efficiency
New Global Innovation Lab Improves R&D Efficiency New innovation lab located in Milwaukee improves prototyping capabilities, driving innovation at an increased speed to market. IN-HOUSE CAPABILITIES BEFORE EXPANSION CASE STUDY Assembly 3D Printing General Prototyping Basic Testing Utilized new in-ho
Slide 10: Appendix
Appendix 10
Slide 11: Historical Quarterly Results
Historical Quarterly Results ($ in millions, except per share) Net Sales & YoY Organic Growth* Adjusted EBITDA and Margin* $161 $159 $159 $156 $41 $150 $40 $40 $39 $145 $146 $37 $142 $138 $35 $34 $34 $34 9% 5% 26% 26% 25% 25% 25% 24% 24% 2% 24% 23% 4% 1% 5% 2% 1% -1% 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q
Slide 12: IT&S Organic Growth by Region
IT&S Organic Growth by Region Regional IT&S Organic Growth by Region Americas EMEA APAC 1Q23 +HT +HSD +LSD 2Q23 +LDD +MSD +MSD 3Q23 +MSD Flat +HT 4Q23 +HSD +MSD +HT 2023 +LDD +MSD +LDD 1Q24 +MSD +HSD +LSD 2Q24 +LSD +MSD -LSD 3Q24 -LSD +LDD -LDD 4Q24 Flat +LSD -MSD 2024 +LSD +HSD -MSD 1Q25 -MSD +LSD
Slide 13: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures (US$ in millions) Consolidated Organic Sales by Quarter Q3 FY25 Organic Sales Fiscal 2023 Fiscal 2024 Fiscal 2025 by Category ETG Organic Sales - Q1 FY23 vs. Q1 FY22 ETG Organic Sales - Q1 FY24 vs. Q1 FY23 ETG Organic Sales - Q1 FY25 vs. Q1 FY24 IT&S Organic Sales
Slide 14: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures (US$ in millions, except per share) Net Sales Adjusted Net Earnings from Continuing Operations Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Enerpac Tool Group $156 $
Slide 15: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures (US$ in millions) Adjusted Selling, general and administrative expenses Q3 FY24 Q3 FY25 Selling, general and administrative expenses $44 $47 Selling, general and administrative expenses % 29.1% 29.6% Selling, general and administrative expenses $44 $47 SG&A Restru
Slide 16: Notes to Reconciliation of Non-GAAP Measures
Notes to Reconciliation of Non-GAAP Measures (1) Approximately $0.4 million of the Q4 fiscal 2024 restructuring charges were recorded in cost of products sold. (2) EBITDA represents net earnings from continuing operations before financing costs, net, income tax expense, and depreciation & amortizati